Dr. Mariangela Tamburello is a researcher at the University of Brescia, within the Department of Molecular and Translational Medicine, Section of Pharmacology, where she holds a PhD and is engaged in translational and preclinical research in oncological pharmacology. Her research focuses on the molecular mechanisms of cancer and the identification of novel therapeutic strategies, with particular attention to adrenocortical carcinoma and testicular cancer. She has spent two years abroad conducting scientific collaborations in Würzburg, Germany, and in the United States (Aurora, Colorado). Dr. Tamburello has contributed to several peer-reviewed publications and collaborates within multidisciplinary research teams aimed at advancing targeted cancer therapies.

Professor Mustofa is a professor in the Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta. He completed his PhD program at the Faculty of Pharmacy, University of Montpellier I in 2000, conducting research on in vitro and in vivo anti-plasmodial activities of various natural and synthetic compounds. Since 2022, he has been served as the President of the Indonesian Association of Pharmacology. His current research focuses on anti-infective and anticancer discovery and development from both natural and synthetic compounds. He also conducted research on pharmacogenetics and pharmacogenomics. He is authors/co-authors of 50 international publications concerning antiplasmodial, anticancer, antibacterial activity of natural and synthetic compounds. Now, he is supervisor for 10 doctoral students whom working about anti-plasmodium, antibacterial-anti-biofilm, anticancer isolated from natural or synthesis and pharmacogenomics.

Dr Ajantha Sinniah is a Senior Lecturer in the Department of Pharmacology, Faculty of Medicine, University Malaya. She obtained her Ph.D. in Biochemical Pharmacology from the William Harvey Research Institute, Queen Mary University of London, where she trained under Professors Roderick Flower and Nick Goulding, internationally recognised leaders in inflammation biology and pharmacology. She subsequently undertook post-doctoral research at the same institute, strengthening her expertise in translational pharmacology and experimental therapeutics, before returning to Malaysia to join University Malaya. Dr Ajantha’s research focuses on cancer biology and immunopharmacology, with an emphasis on translational, mechanism-driven studies in colorectal cancer. She supervises Ph.D. and Master’s students in multidisciplinary approaches including molecular biology, cell-based models, pharmacological profiling, and mechanistic pathway analysis to address drug resistance. She previously served as Head of the AAALAC-accredited Animal Experimental Unit at University Malaya. Her current work investigates Annexin A1-mediated chemoresistance and cancer stem cell–associated signalling pathways in colorectal cancer to identify novel therapeutic strategies.

Dr. Mariangela Tamburello is a researcher at the University of Brescia, within the Department of Molecular and Translational Medicine, Section of Pharmacology, where she holds a PhD and is engaged in translational and preclinical research in oncological pharmacology. Her research focuses on the molecular mechanisms of cancer and the identification of novel therapeutic strategies, with particular attention to adrenocortical carcinoma and testicular cancer. She has spent two years abroad conducting scientific collaborations in Würzburg, Germany, and in the United States (Aurora, Colorado). Dr. Tamburello has contributed to several peer-reviewed publications and collaborates within multidisciplinary research teams aimed at advancing targeted cancer therapies.

Katia Sirna is a PhD researcher in Medicinal Chemistry and Pharmacology at the University of Helsinki. She earned her Master’s degree in Pharmaceutical Chemistry and Technology from the University of Pavia (Italy) and first joined the University of Helsinki during her MSc thesis as an exchange student. During this time, she developed a strong interest in designing molecules capable of modulating cellular behaviour, which led her to begin her doctoral studies in January 2022. Katia now works within a multidisciplinary project aimed at discovering new allosteric modulators of protein kinase C (PKC), with potential applications in treating heart disease and cancer. Her research focuses on the sustainable design and synthesis of novel PKC agonists, as well as investigating their effects in biological models.